| __timestamp | Mesoblast Limited | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 520990000000 |
| Thursday, January 1, 2015 | 23783000 | 535405000000 |
| Friday, January 1, 2016 | 29763000 | 558755000000 |
| Sunday, January 1, 2017 | 12065000 | 495921000000 |
| Monday, January 1, 2018 | 5508000 | 659690000000 |
| Tuesday, January 1, 2019 | 75173000 | 1089764000000 |
| Wednesday, January 1, 2020 | 81497000 | 994308000000 |
| Friday, January 1, 2021 | 85731000 | 1106846000000 |
| Saturday, January 1, 2022 | 63572000 | 1244072000000 |
| Sunday, January 1, 2023 | 54922000 | 1431505000000 |
| Monday, January 1, 2024 | 41070000 | 1431505000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost efficiency is crucial. Takeda Pharmaceutical Company Limited and Mesoblast Limited, two giants in the industry, present a fascinating study in contrasts. Over the past decade, Takeda has consistently demonstrated a robust cost of revenue, peaking at approximately 1.43 trillion in 2023. This represents a staggering 175% increase from 2014, showcasing their strategic prowess in managing expenses.
Conversely, Mesoblast Limited, while smaller in scale, has shown a more volatile trajectory. Their cost of revenue peaked in 2021 at around 85.7 million, a significant leap from their 2014 figure. However, the subsequent decline to 41 million in 2024 suggests challenges in maintaining efficiency.
This comparison underscores the diverse strategies employed by pharmaceutical companies in navigating financial landscapes, offering valuable insights for investors and industry analysts alike.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Biogen Inc. and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Mesoblast Limited
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited